Tryp Therapeutics Inc.
CSE: TRYP
Company Overview
Tryp Therapeutics is a clinical stage drug development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$0.17
Diluted EPS (ttm)
Management Team
Dr. James P. Gilligan MSIB, Ph.D.
Interim CEO, Pres & Chief Scientific Officer
Dr. James S. Kuo M.B.A., M.D.
Co-Founder & Director
Mr. Thomas D'Orazio B.Sc., M.B.A.
Chief Operating Officer
Mr. Sidney Taubenfeld R.Ph
Chief Operating Officer
Ms. Joy Willis
Director of Investor Relations
Key Highlights
Market Capitalization
$5,148,835
Shares Outstanding
60,302,222
Shares Short (% of Float)
()
Insider Ownership
48%